Compound induces selective apoptosis in AML

AML cells
Image by Lance Liotta
Researchers say they have discovered a compound that can overcome resistance to apoptosis in acute myeloid leukemia (AML). The compound, BTSA1, works by activating the BCL-2 family protein BAX. BTSA1 prompted apoptosis in leukemia cells while sparing healthy cells. It also suppressed AML in mice without producing side effects. Evripidis Gavathiotis, PhD, of Albert Einstein College of Medicine in Bronx, New York, and his colleagues described these results in Cancer Cell. [Read Article]

CHMP recommends new formulation of pegaspargase

Micrograph showing ALL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorization for lyophilized pegaspargase (ONCASPAR). If approved, the product would be used as a component of antineoplastic therapy in patients of all ages who have acute lymphoblastic leukemia (ALL). The product is a freeze-dried formulation of liquid pegaspargase, which is already approved for the aforementioned indication. The CHMP’s recommendation regarding lyophilized pegaspargase will be submitted to the European Commission (EC). [Read Article]

Cryotherapy can reduce signs of CIPN

Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer
A new study suggests cryotherapy can reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Researchers found that having chemotherapy patients wear frozen gloves and socks for 90-minute periods significantly reduced the incidence of CIPN symptoms. Hiroshi Ishiguro, MD, PhD, of International University of Health and Welfare Hospital in Tochigi, Japan, and colleagues reported these findings in the Journal of the National Cancer Institute. [Read Article]